Jaknat (Tofacitinib 11mg)

Jaknat (Tofacitinib 11mg) is an approved Janus kinases (JAKs) inhibitor used for treating various medical conditions. These include moderately to severely active rheumatoid arthritis in adult patients who have not responded well to methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs). Tofacitinib can be used alone or in combination with methotrexate or other non-biologic DMARDs. However, it should not be used with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.

Tofacitinib is also used for active psoriatic arthritis in adult patients who have not responded well to methotrexate or other DMARDs. Similar to its use in rheumatoid arthritis, Tofacitinib can be used alone or in combination with other non-biologic DMARDs, but not with biologic DMARDs or potent immunosuppressants like azathioprine and cyclosporine.

In addition, Tofacitinib is used for moderately to severely active ulcerative colitis (UC) in adult patients who have not responded well to TNF blockers or are intolerant to them. However, using Tofacitinib in combination with biologic therapies for UC or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Finally, Tofacitinib is used for active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients aged two years and older. The oral solution of Tofacitinib is indicated for this use. But, it should not be used together with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.

Tofacitinib DOSAGE

To treat Rheumatoid Arthritis, Tofacitinib is recommended at a dose of 5 mg twice daily or 11 mg once daily. In patients with moderate to severe renal impairment or moderate hepatic impairment, a dose of 5 mg once daily is recommended. However, Tofacitinib 11mg should not be used in patients with severe hepatic impairment. Studies suggest that turmeric supplements may help alleviate arthritis and joint pain.

For Psoriatic Arthritis, Tofacitinib is recommended at a dose of 5 mg twice daily in combination with nonbiologic DMARDs, or 11 mg once daily in combination with nonbiologic DMARDs. In patients with moderate to severe renal impairment or moderate hepatic impairment, a dose of 5 mg once daily is recommended. However, Tofacitinib 11mg should not be used in patients with severe hepatic impairment.

To treat Ulcerative Colitis, Tofacitinib is recommended at a dose of 10 mg twice daily or 22 mg once daily for 8 weeks to induce remission. After 8 weeks, patients should be evaluated and transitioned to maintenance therapy based on their therapeutic response. If necessary, Tofacitinib can be continued at 10 mg twice daily or 22 mg once daily for up to 16 weeks. If a sufficient therapeutic response is not achieved after 16 weeks, Tofacitinib should be discontinued. For maintenance therapy, the recommended dose is 5 mg twice daily or 11 mg once daily. If a patient experiences a loss of response during maintenance treatment, Tofacitinib 10 mg twice daily or 22 mg once daily may be considered, but only for the shortest duration possible, with careful consideration of the benefits and risks for the individual patient. The lowest effective dose needed to maintain a response should be used. Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment.

To treat Polyarticular Course Juvenile Idiopathic Arthritis, Tofacitinib Oral Solution is recommended at a dose of 5 mg twice daily or weight-based equivalent twice daily. Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment. Please refer to the full prescribing information for further details.

Tofacitinib Side Effects：

TOFACITINIB 5MG/11MG is an immunosuppressive medication that can lower the body's ability to fight infections, including serious ones like tuberculosis, bacterial, fungal, or viral infections that can spread throughout the body. In some cases, these infections have been fatal. Prior to and during treatment with TOFACITINIB 5MG/11MG, it is crucial that your healthcare provider tests you for tuberculosis and monitors you closely for signs of infection.

Do not take TOFACITINIB 5MG/11MG if you currently have an infection, unless your healthcare provider deems it safe to do so. Before starting treatment, let your healthcare provider know if you have a history of infections, diabetes, chronic lung disease, HIV, weak immune system, or if you reside in or have traveled to areas where fungal infections are common. If you experience symptoms of infection like fever, cough, or diarrhea, seek medical attention immediately.

Using TOFACITINIB 5MG/11MG may heighten the risk of specific types of cancer, such as lymphoma and skin cancer. Therefore, it is important to inform your healthcare provider if you have ever had cancer. Moreover, some individuals who have taken TOFACITINIB in conjunction with certain medications have experienced an issue with white blood cells multiplying uncontrollably.

Taking TOFACITINIB 5MG/11MG can also increase the chance of stomach or intestinal tears, particularly if you are also taking nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Let your healthcare provider know if you have had diverticulitis or ulcers in your stomach or intestines. Contact your healthcare provider immediately if you experience persistent fever and stomach-area pain, or a change in bowel habits.

While you are on TOFACITINIB 5MG/11MG, your healthcare provider should regularly monitor specific blood tests, including lymphocyte, neutrophil, and red blood cell counts, as well as liver tests. If any of these test results are abnormal, your healthcare provider may temporarily stop treatment. Additionally, your healthcare provider may need to regularly check your blood cholesterol levels, as normal levels are important for good heart health.

Buy tofacitinib online：

Tofacitinib can be purchased online from an Indian pharmacy at a cost of 8% of the brand-name Tofacitinib.

Tofacitinib PI

For additional prescribing information, please contact our customer service and request the "FDA Prescribing Information."